期刊文献+

白族地区铜绿假单胞菌临床分布与耐药性分析 被引量:3

Distribution and drug resistance of clinical isolates of Pseudomonas aeruginosain Bai region
原文传递
导出
摘要 目的探讨大理学院附属医院铜绿假单胞菌(PAE)的临床分布及耐药性,为临床使用抗菌药物提供依据。方法采用K-B法对2011年临床收集的74株PAE进行药敏试验,并分析其耐药性。结果 PAE主要来源于痰标本,其次创面分泌物,分别占78.4%和10.8%;PAE对磺胺甲噁唑/甲氧苄啶和头孢呋辛耐药率最高,达100.0%,其次为氨苄西林/舒巴坦、庆大霉素、头孢噻肟和哌拉西林,耐药率分别为95.9%、85.1%、82.4%和79.7%;哌拉西林/他唑巴坦、亚胺培南、头孢吡肟和阿米卡星敏感率较高,分别为71.6%、66.2%、73.0%和87.8%,头孢他啶敏感率最高,达90.5%。结论 PAE临床分布广泛,耐药严重,应加强耐药性监测,合理选用抗菌药物。 OBJECTIVE To investigate the distribution and antibiotics resistance of Pseudornonas aeruginosa isolated from the Affiliated Hospital of Dali University and offer basis for the clinical application of drugs. METHODS A total of 74 strains of P. aeruginosa were collected from the hospital in 2011. The susceptibility testing was performed to analyze the drug resistance by Kirby-Bauer method. RESULTS There were 78.4% of the P. aeruginosa strains which were isolated from sputum specimens and 10.8% of the P. aeruginosa strains which were isolated from wound secretions. The drug resistance rates of the P. aeruginosa strains to trimethoprim- sulfamethoxazole and cefuroxime were 100. 0%. the resistance rates to ampicillin/sulbactam, gentamycin, cefotaxime and piperacillin were 95.9%, 85.1 %, 82.4% and 79.7%, respectively. The drug susceptibility rates of the P. aeruginosa strains to piperacillin/tazobactam, imipenem, cefepime and amikacin were 71.6 %, 66.2 %, 73.0%, and 87. 8%, respectively, and the drug susceptibility rate to ceftazidime was highest (90. 5%). CONCLUSION The P. aeruginosa strains distribute widely in the hospital, the drug resistance of which is serious. It is necessary to strengthen the monitoring of drug resistance so as to reasonably use antibiotics.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2013年第7期1707-1708,共2页 Chinese Journal of Nosocomiology
关键词 铜绿假单胞菌 临床分布 耐药性 Pseudomonas aeruginosa Clinical distribution Drug resistance
  • 相关文献

参考文献5

二级参考文献31

  • 1Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supple- ment[S]. M100-S20. CLSI,2010.
  • 2Walkty A, DeCorby M, Nichol K, et al, Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study[J]. Diagn Microbiol Infect Dis, 2008, 61:217-221.
  • 3Zavascki A P, Carvalhaes resistant Pseudomonas C G, Picao R C, et al. Multidrugaeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy[J]. Expert Rev Anti Infect Ther, 2010,8(1):71-93.
  • 4Paterson D L. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species[J]. Clin Infect Dis, 2006, 43:S43-S48.
  • 5Suairez C, Pefia C, Tubau F, et al. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections[J]. Jlnfect, 2009, 58:285-290.
  • 6Wang H, Chen M J, Ni Y X, et al. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008[J]. lnt JAntimicrob Agents, 2010, 35: 227-234.
  • 7Hirsch E B, Tam V H. Pseudomonas aeruginosa infection on patient outcomes[J]. Expert Rev Pharmacoeeonom Outcomes Res, 2010, 10(4): 441-451.
  • 8Aloush V, Venezia S N, Igra Y S, et al. Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact[J]. Antimicrob Agents Chemother, 2006, 50(1): 43-48.
  • 9Cardoso O, Alves A F, Leitao R. Surveillance of antimicrobial susceptibility of Pseudomonas aeruginosa clinical isolates from a central hospital in Portuga[J]. J Antimicrob Agents, 2007, 60(2): 452-454.
  • 10Pakyz A L, Oinonen M, Polk R E, et al. Relationship of carbapenem restriction in 22 university teaching hospital to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2009, 53(5): 1983-1986.

共引文献106

同被引文献31

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部